摘要开发新的放射性药物对于核医学分子影像的发展至关重要.近年来,基于放射性金属核素(如64Cu)的放射性药物的开发取得了显著进展.Cu是人体必需的微量金属元素.Cu代谢紊乱会引起遗传性威尔逊病(Wilson disease)和门克斯病(Menkes disease),还在恶性肿瘤的发生中起着重要的作用.除了用于探针的放射性标记,64Cu还可用于Cu代谢异常疾病的PET诊断显像.64CuCl2可用于跟踪人体Cu代谢中Cu离子的动态流动.该文对64CuCl2用于遗传性Cu代谢异常疾病和高Cu代谢性肿瘤的PET显像诊断的研究进展进行了综述.

abstractsDevelopment of new radiopharmaceuticals is crucial for the advance of nuclear medicine and molecular imaging.In recent years,significant progress has been made in the development of radiopharmaceuticals based on radioactive metal nuclides such as 64Cu.Copper is a transition metal element necessary for human physiology.Disorders of copper metabolism not only cause hereditary Wilson disease and Menkes disease,but also play an important role in the development of malignant tumors.In addition to radiolabeling for probes,64Cu can be used for PET diagnostic imaging of copper metabolism disorders.64CuCl2 is a useful radiotracer that can be used to track the dynamic flow of copper ions in human body copper metabolism by PET imaging.In recent years,many preclinical and clinical studies of 64CuCl2 radiotracer have achieved good results,and have attracted a lot of attention in the field of nuclear medicine and molecular imaging.In this article,the progress in the development of 64CuCl2 as a radiotracer for PET diagnostic imaging of hereditary copper metabolism disorders and copper hypermetabolic tumors is reviewed,and further research studies and potential clinical application of 64CuCl2 PET/CT imaging is prospected.